New drug before surgery may shrink hard-to-treat colorectal cancers
NCT ID NCT07352280
First seen Feb 01, 2026 · Last updated May 22, 2026 · Updated 11 times
Summary
This study looks at whether giving the drug tislelizumab before surgery can help people with a specific genetic type of colorectal cancer (dMMR/MSI-H). About 30 adults with stage II or III cancer will receive three doses of tislelizumab, then have surgery to remove the tumor. Researchers will check if the cancer disappears completely and monitor side effects for up to 5 years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER (DMMR/MSI-H CRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Undefined, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.